Literature DB >> 31769731

Heparin chromatography as an in vitro predictor for antibody clearance rate through pinocytosis.

Thomas E Kraft1, Wolfgang F Richter2, Thomas Emrich1, Alexander Knaupp1, Michaela Schuster1, Andreas Wolfert1, Hubert Kettenberger1.   

Abstract

The pharmacokinetic (PK) properties of therapeutic antibodies directly affect efficacy, dose and dose intervals, application route and tissue penetration. In indications where health-care providers and patients can choose between several efficacious and safe therapeutic options, convenience (determined by dosing interval or route of application), which is mainly driven by PK properties, can affect drug selection. Therapeutic antibodies can have greatly different PK even if they have identical Fc domains and show no target-mediated drug disposition. Biophysical properties like surface charge or hydrophobicity, and binding to surrogates for high abundant off-targets (e.g., baculovirus particles, Chinese hamster ovary cell membrane proteins) were proposed to be responsible for these differences. Here, we used heparin chromatography to separate a polyclonal mix of endogenous human IgGs (IVIG) into fractions that differ in their PK properties. Heparin was chosen as a surrogate for highly negatively charged glycocalyx components on endothelial cells, which are among the main contributors to nonspecific clearance. By directly correlating heparin retention time with clearance, we identified heparin chromatography as a tool to assess differences in unspecific cell-surface interaction and the likelihood for increased pinocytotic uptake and degradation. Building on these results, we combined predictors for FcRn-mediated recycling and cell-surface interaction. The combination of heparin and FcRn chromatography allow identification of antibodies with abnormal PK by mimicking the major root causes for fast, non-target-mediated, clearance of therapeutic, Fc-containing proteins.

Entities:  

Keywords:  FcRn; Pharmacokinetics; clearance; heparin; neonatal Fc receptor; pinocytosis; prediction

Mesh:

Substances:

Year:  2020        PMID: 31769731      PMCID: PMC6927760          DOI: 10.1080/19420862.2019.1683432

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  38 in total

1.  pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling.

Authors:  M Jack Borrok; Yanli Wu; Nurten Beyaz; Xiang-Qing Yu; Vaheh Oganesyan; William F Dall'Acqua; Ping Tsui
Journal:  J Biol Chem       Date:  2014-12-23       Impact factor: 5.157

2.  Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics.

Authors:  Amita Datta-Mannan; Arunkumar Thangaraju; Donmienne Leung; Ying Tang; Derrick R Witcher; Jirong Lu; Victor J Wroblewski
Journal:  MAbs       Date:  2015       Impact factor: 5.857

3.  A Two-pronged Binding Mechanism of IgG to the Neonatal Fc Receptor Controls Complex Stability and IgG Serum Half-life.

Authors:  Pernille Foged Jensen; Angela Schoch; Vincent Larraillet; Maximiliane Hilger; Tilman Schlothauer; Thomas Emrich; Kasper Dyrberg Rand
Journal:  Mol Cell Proteomics       Date:  2017-01-06       Impact factor: 5.911

4.  Aberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeys.

Authors:  Amita Datta-Mannan; Johnny E Croy; Linda Schirtzinger; Stacy Torgerson; Matthew Breyer; Victor J Wroblewski
Journal:  MAbs       Date:  2016-07       Impact factor: 5.857

5.  Hematopoietic cells as site of first-pass catabolism after subcutaneous dosing and contributors to systemic clearance of a monoclonal antibody in mice.

Authors:  Wolfgang F Richter; Gregory J Christianson; Nicolas Frances; Hans Peter Grimm; Gabriele Proetzel; Derry C Roopenian
Journal:  MAbs       Date:  2018-05-09       Impact factor: 5.857

6.  Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding.

Authors:  Jan Terje Andersen; Muluneh Bekele Daba; Gøril Berntzen; Terje E Michaelsen; Inger Sandlie
Journal:  J Biol Chem       Date:  2009-12-14       Impact factor: 5.157

7.  The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies.

Authors:  Amita Datta-Mannan; Jirong Lu; Derrick R Witcher; Donmienne Leung; Ying Tang; Victor J Wroblewski
Journal:  MAbs       Date:  2015-09-04       Impact factor: 5.857

8.  Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.

Authors:  Herren Wu; David S Pfarr; Syd Johnson; Yambasu A Brewah; Robert M Woods; Nita K Patel; Wendy I White; James F Young; Peter A Kiener
Journal:  J Mol Biol       Date:  2007-02-20       Impact factor: 5.469

Review 9.  Elimination mechanisms of therapeutic monoclonal antibodies.

Authors:  Mohammad A Tabrizi; Chih-Ming L Tseng; Lorin K Roskos
Journal:  Drug Discov Today       Date:  2006-01       Impact factor: 7.851

10.  A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.

Authors:  Colby A Souders; Stuart C Nelson; Yang Wang; Andrew R Crowley; Mark S Klempner; William Thomas
Journal:  MAbs       Date:  2015       Impact factor: 5.857

View more
  11 in total

1.  Minimal Physiologically-based Pharmacokinetic Model to Investigate the Effect of Charge on the Pharmacokinetics of Humanized anti-HCV-E2 IgG Antibodies in Sprague-Dawley Rats.

Authors:  Deni Hardiansyah; Chee Meng Ng
Journal:  Pharm Res       Date:  2022-03-04       Impact factor: 4.200

2.  Assessing the binding properties of the anti-PD-1 antibody landscape using label-free biosensors.

Authors:  Michael E Brown; Daniel Bedinger; Asparouh Lilov; Palaniswami Rathanaswami; Maximiliano Vásquez; Stéphanie Durand; Ian Wallace-Moyer; Lihui Zhong; Juergen H Nett; Irina Burnina; Isabelle Caffry; Heather Lynaugh; Melanie Sinclair; Tingwan Sun; John Bukowski; Yingda Xu; Yasmina Noubia Abdiche
Journal:  PLoS One       Date:  2020-03-05       Impact factor: 3.240

3.  Interaction of clinical-stage antibodies with heme predicts their physiochemical and binding qualities.

Authors:  Maxime Lecerf; Alexia Kanyavuz; Sofia Rossini; Jordan D Dimitrov
Journal:  Commun Biol       Date:  2021-03-23

4.  Structure-based charge calculations for predicting isoelectric point, viscosity, clearance, and profiling antibody therapeutics.

Authors:  Nels Thorsteinson; John R Gunn; Kenneth Kelly; Will Long; Paul Labute
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

5.  Effect of variable domain charge on in vitro and in vivo disposition of monoclonal antibodies.

Authors:  Shufang Liu; Ashwni Verma; Hubert Kettenberger; Wolfgang F Richter; Dhaval K Shah
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

Review 6.  Viro-antibody therapy: engineering oncolytic viruses for genetic delivery of diverse antibody-based biotherapeutics.

Authors:  Roland E Kontermann; Guy Ungerechts; Dirk M Nettelbeck
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

Review 7.  Toward Drug-Like Multispecific Antibodies by Design.

Authors:  Manali S Sawant; Craig N Streu; Lina Wu; Peter M Tessier
Journal:  Int J Mol Sci       Date:  2020-10-12       Impact factor: 5.923

8.  Pharmacokinetic prediction of an antibody in mice based on an in vitro cell-based approach using target receptor-expressing cells.

Authors:  Yuki Noguchi; Kazuhisa Ozeki; Hidetaka Akita
Journal:  Sci Rep       Date:  2020-10-01       Impact factor: 4.379

9.  Functional in vitro assessment of modified antibodies: Impact of label on protein properties.

Authors:  Martin R Edelmann; Simon Hauri
Journal:  PLoS One       Date:  2021-09-16       Impact factor: 3.240

Review 10.  Discovery-stage identification of drug-like antibodies using emerging experimental and computational methods.

Authors:  Emily K Makowski; Lina Wu; Priyanka Gupta; Peter M Tessier
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.